Somatostatin and gamma-aminobutyric acid inhibit interleukin-1β- stimulated release of interleukin-6 from rat C6 glioma cells

NeuroImmunoModulation

Volumn 11, Issue 5, 2004, Pages 332-340

  Spangelo, Bryan L ^a   Horrell, Scott ^a   Goodwin, Amy L ^a   Shroff, Sachin ^a   Jarvis, W David ^b,c  

^a UNIVERSITY OF NEVADA   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c Dominion Diagnostics   (United States)

Author keywords

Aminobutyric acid; Interleukin 1; Interleukin 6; p38; Somatostatin

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 AMINOBUTYRIC ACID; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; ISOPRENALINE; LYSOPHOSPHATIDYLCHOLINE; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROTRANSMITTER; PROTEIN INHIBITOR; SOMATOSTATIN 14; SOMATOSTATIN 28; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL STIMULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; EXPOSURE; GLIOBLASTOMA; GLIOMA CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CELL LINE, TUMOR; DRUG INTERACTIONS; ENZYME INHIBITORS; GAMMA-AMINOBUTYRIC ACID; GLIOMA; HYBRIDOMAS; INTERLEUKIN-1; INTERLEUKIN-6; MITOGEN-ACTIVATED PROTEIN KINASES; NEUROIMMUNOMODULATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; SECOND MESSENGER SYSTEMS; SOMATOSTATIN; SOMATOSTATIN-28;

EID: 4444232494     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079414     Document Type: Article

References (31)

1. Zhao B, Schwartz JP: Involvement of cytokines in normal CNS development and neurological diseases: Recent progress and perspectives. J Neurosci Res 1998;52:7-16.
2. Heininger K: A unifying hypothesis of Alzheimer's disease. II. Pathophysiological processes. Hum Psychopharmacol Clin Exp 1999;14:525-581.
3. Vitkovic L, Konsman JP, Bockaert J, Dantzer R, Homburger V, Jacque C: Cytokine signals propagate through the brain. Mol Psychiatry 2000;5:604-615.
4. Davies P, Katzman R, Terry RD: Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer's disease and Alzheimer's senile dementia. Nature 1980;288:279-280.
5. Beal MF, Mazurek MF, Tran VT, Chattha G, Bird ED, Martin JB: Reduced numbers of somatostatin receptor in the cerebral cortex in Alzheimer's disease. Science 1985;229:289-291.
6. Bissotte G, Cook L, Smith W, Dole KC, Crain B, Nemeroff CB: Regional neuropeptide pathology in Alzheimer's disease: Corticotropinreleasing factor and somatostatin. J Alzheimer's Dis 1998;1:91-105.
7. Davis KL, Mohs RC, Marin DB, Purohit P, Perl DP, Lantz M, Austin G, Haroutunian V: Neuropeptide abnormalities in patients with early Alzheimer disease. Arch Gen Psychiatry 1999;56:981-987.
8. MacLeod RM, Gorospe WC, Hughes FM, Spangelo BL: Synthesis, release, and actions of interleukin-6 in brain and neuroendocrine tissues: Methods and overview; in DeSouza EB (ed): Neurobiology of Cytokines, part B. New York, Academic Press, 1993, vol 17, pp 3-15.
9. Zumwalt J, Thunstrom B, Spangelo BL: Interleukin-1β and catecholamines synergistically stimulate interleukin-6 release from rat C6 glioma cells in vitro: A potential role for lysophosphatidylcholine. Endocrinology 1999;140:888-896.
10. Cattaneo MG, Taylor JE, Culler MD, Nisoli E, Vicentini LM: Selective stimulation of somatostatin receptor subtypes: Differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells. FEBS Lett 2000;481:271-276.
11. Feindt J, Becker I, Blomer U, Hugo HH, Mehdorn HM, Krisch B, Mentlein R: Expression of somatostatin receptor subtypes in cultured astrocytes and gliomas. J Neurochem 1995;65:1997-2005.
12. Feindt J, Mentlein R, Krisch B: Time-dependent influence of the somatostatin analogue octreotide on the proliferation of rat astrocytes and glioma cells. Brain Res 1997;746:309-313.
13. Craft S, Asthana S, Newcomer JH, Wilkinson CW, Matos IT, Baker LD, Cherrier M, Lofgreen C, Latendresse S, Petrova A, Plymate S, Raskind M, Grimwood K, Veith RC: Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry 1999;56:1135-1140.
14. Kjeldsen TH, Hansen EW, Christensen JD, Moesby L: Baclofen influences lipopolysaccharide-mediated interleukin-6 release from murine pituicytes. Eur J Pharm 2002;451:209-215.
15. Samland H, Huitron-Resendiz S, Masliah E, Criado J, Henriksen SJ, Campbell IL: Profound increase in sensitivity to glutaminergicbut not cholinergic agonist-induced seizures in transgenic mice with astrocyte production of IL-6. J Neurosci Res 2003;73:176-187.
16. Komorowski J, Stepien H: Somatostatin (SRIF) stimulates the release of interleukin-6 (IL-6) from human peripheral blood monocytes (PBM) in vitro. Neuropeptides 1995;29:77-81.
17. Peluso G, Petillo O, Melone MA, Mazzarella G, Ranieri M, Tajana GF: Modulation of cytokine production in activated human monocytes by somatostatin. Neuropeptides 1996;30:443-451.
18. Grimaldi M, Florio T, Schettini G: Somatostatin inhibits interleukin-6 release from rat cortical type I astrocytes via the inhibition of adenylyl cyclase. Biochem Biophys Res Commun 1997;235:242-248.
19. Marcus JS, Karackattu SL, Fleegal MA, Sumners C: Cytokine-stimulated inducible nitric oxide synthase expression in astroglia: Role of Erk mitogen-activated protein kinase and NFIκB. Glia 2003;41:152-160.
20. Parker LC, Luheshi GN, Rothwell NJ, Pinteaux E: IL-1β signaling in glial cells in wildtype and IL-1RI deficient mice. Br J Pharmacol 2002;136:312-320.
21. Dunn SL, Young EA, Hall MD, McNulty S: Activation of astrocyte intracellular signaling pathways by interleukin-1 in rat primary striatal cultures. Glia 2002;37:31-42.
22. Simi A, Porsmyr-Palmertz M, Hjerten A, Ingelman-Sundberg M, Tindberg N: The neuroprotective agents chlomethiazole and SB203580 inhibit IL-1β signaling but not its biosynthesis in rat cortical glial cells. J Neurochem 2002;83:727-737.
23. Manning AM, Davis RJ: Targeting JNK for therapeutic benefit: From junk to gold? Nat Rev Drug Discov 2003;2:554-565.
24. Gallo KA, Johnson GL: Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat Rev Mol Cell Biol 2002;3:663-672.
25. Jarvis WD, Fornari FA, Auer KL, Freemerman AJ, Szabo E, Birrer MJ, Johnson CR, Barbour SE, Dent P, Grant S: Coordinate regulation of stress-activated protein kinase (SAPK) and mitogen-activated protein kinase (MAPK) cascades in the apoptotic actions of ceramide and sphingosine in human myeloid leukemia cells. Mol Pharmacol 1997;52:935-947.
26. Verheij M, Bose R, Lin X-H, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, Haimovitz-Friedman A, Fuks ZY, Kolesnick RN: Requirement for ceramideinitiated stress-activated protein kinase/c-Jun aminoterminal kinase (SAPK/JNK) signalling in stress-induced apoptosis. Nature 1996;380:75-79.
27. Jarvis WD, Johnson CR, Fornari FA, Park J-S, Dent P, Grant S: Evidence that the apoptotic actions of etoposide and teniposide are independent of SAPK-JNK activity and c-Jun/AP1-mediated transregulation. J Pharmacol Exp Ther 1999;290:1384-1392.
28. Sawai H, Okazaki T, Yamamoto T, Okano H, Takeda Y, Tashima M, Sawada H, Okuma M, Ishikura H, Umehara H, Doma N: Requirement of AP-1 for ceramide-induced apoptosis in human leukemia HL-60 cells. J Biol Chem 1995;270:27326-27331.
29. Johnson CR, Jiffar T, Ruvolo PP, Jarvis WD: Requirement for SAPK-JNK cascade signaling in the induction of apoptosis by ribosomally gated stress in REH human lymphoid leukemia cells. Leukemia, 2003;17:2140-2149.
30. Daun JM, Fenton MJ: Interleukin-1/Toll receptor family members: Receptor structure and signal transduction pathways. J Interfer Cyto Res 2000;20:843-855.
31. Jing Q, Xin SM, Zhang WB, Wang P, Qin YW, Pei G: Lysophosphatidylcholine activates p38 and p42/44 mitogen-activated protein kinases in monocytic THP-1 cells, but only p38 activation is involved in its stimulated chemotaxis. Circ Res 2000;87:52-59.